Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Language
Document Type
Year range
1.
Carlo Fischer; Tongai Gibson Maponga; Anges Yadouleton; Nuro Abilio; Emmanuel Aboce; Praise Adewumi; Pedro Afonso; Jewelna Akorli; Soa Fy Andriamandimby; Latifa Anga; Yvonne Ashong; Mohamed Amine Beloufa; Aicha Bensalem; Richard Birtles; Anicet Luc Magloire Boumba; Freddie Bwanga; Mike Chaponda; Paradzai Chibukira; R Matthew Chico; Justin Chileshe; Wonderful Choga; Gershom Chongwe; Assana Cisse; Fatoumata Cisse; Umberto D Alessandro; Xavier de Lamballerie; Joana F.M. de Morais; Fawzi Derrar; Ndongo Dia; Youssouf Diarra; Lassina Doumbia; Christian Drosten; Philippe Dussart; Richard Echodu; Tom Luedde; Abdelmajid Eloualid; Ousmane Faye; Torsten Feldt; Anna Fruehauf; Simani Gaseitsiwe; Afiwa Halatoko; Pauliana-Vanessa Ilouga; Nalia Ismael; Ronan Jambou; Sheikh Jarju; Antje Kamprad; Ben Katowa; John Kayiwa; Leonard Kingwara; Ousmane Koita; Vincent Lacoste; Adamou Lagare; Olfert Landt; Sonia Etenna Lekana-Douki; Jean-Bernard Lekana-Douki; Etuhole Iipumbu; Hugues Loemba; Julius Lutwama; Santou Mamadou; Issaka Maman; Brendon Manyisa; Pedro A. Martinez; Japhet Matoba; Lusia Mhuulu; Andres Moreira-Soto; Sikhulile Moyo; Judy Mwangi; Nadine Ndilimabaka; Charity Angella Nassuna; Mamadou Ousmane Ndiath; Emmanuel Nepolo; Richard Njouom; Jalal Nourlil; Steven Ger Nyanjom; Eddy Okoth Odari; Alfred Okeng; Jean Bienvenue Ouoba; Michael Owusu; Irene Owusu Donkor; Karabo Kristen Phadu; Richard Odame Phillips; Wolfgang Preiser; Pierre Roques; Vurayai Ruhanya; Fortune Salah; Sourakatou Salifou; Amadou Alpha Sall; Augustina Angelina Sylverken; Paul Alain Tagnouokam-Ngoupo; Zekiba Tarnagda; Francis Olivier Tchikaya; Noel Tordo; Tafese Beyene Tufa; Jan Felix Drexler.
medrxiv; 2024.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2024.02.27.24303356

ABSTRACT

Background: In mid-November 2021, the SARS-CoV-2 Omicron BA.1 variant was detected in Southern Africa, prompting international travel restrictions of unclear effectiveness that exacted a substantial economic toll. Methods: Amidst the BA.1 wave, we tested 13,294 COVID-19 patients in 24 African countries between mid-2021 to early 2022 for BA.1 and Delta variants using real-time reverse transcription-PCR tests. The diagnostic precision of the assays was evaluated by high-throughput sequencing in four countries. The observed BA.1 spread was compared to mobility-based mathematical simulations. Findings: By November-December 2021, BA.1 had replaced the Delta variant in all African sub-regions following a South-North gradient, with a median Rt of 2.4 up to 30 days before BA.1 became predominant. PCR-based South-North spread was in agreement with phylogeographic reconstructions relying on 939 SARS-CoV-2 genomes from GISAID. PCR-based reconstructions of country-level BA.1 predominance correlated significantly in time with the emergence of BA.1 genomic sequences on GISAID (p=0.0035, cor=0.70). First BA.1 detections in affluent settings beyond Africa were predicted adequately in time by mobility-based mathematical simulations (p<0.0001). BA.1-infected inbound travelers departing from five continents were identified in five Western countries and one Northern African country by late November/early December 2021, highlighting fast global BA.1 spread aided by international travel. Interpretation: Unilateral travel bans were poorly effective because by the time they came into effect, BA.1 was already widespread in Africa and beyond. PCR-based variant typing combined with mobility-based mathematical modelling can inform rapidly and cost-efficiently on Rt, spread to inform non-pharmaceutical interventions.


Subject(s)
COVID-19
2.
researchsquare; 2021.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-290291.v1

ABSTRACT

Back ground: Corona Virus Disease 2019 (COVID 19) in Uganda was first reported in a male traveler from Dubai on 21st March, 2020 shortly after WHO had announced the condition as a global pandemic. Timely laboratory diagnosis of COVID -19 for all samples from both symptomatic and asymptomatic patients was observed as key in containing the pandemic and breaking the chain of transmission. However, there was a challenge of limited resources required for testing SARS-COV-2 in low and middle income countries. To mitigate this, a study was conducted to evaluate a sample pooling strategy for COVI-19 using real time PCR. The cost implication and the turn around time of pooled sample testing versus individual sample testing were also compared.Methods: In this study, 1260 randomly selected samples submitted to Uganda Virus Research Institute for analysis were batched in pools of 5, 10, and 15. The pools were then extracted using a Qiagen kit. Both individual and pooled RNA were screened for the SARS-COV-2 E gene using a Berlin kit. Results: Out of 1260 samples tested, 21 pools were positive in pools of 5 samples, 16 were positive in pools of 10 and 14 were positive in pools of 15 samples. The study also revealed that the pooling strategy helps to save a lot on resources, time and expands diagnostic capabilities without affecting the sensitivity of the test in areas with low SARS-COV-2 prevalence.Conclusion: This study demonstrated that the pooling strategy for COVID-19 reduced on the turnaround time and there was a substantial increase in the overall testing capacity with limited resources as compared to individual testing.


Subject(s)
COVID-19 , Virus Diseases
SELECTION OF CITATIONS
SEARCH DETAIL